Cargando…

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recomme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Telli, Melinda L., Tolaney, Sara M., Shapiro, Geoffrey I., Middleton, Mark, Lord, Simon R., Arkenau, Hendrik Tobias, Tutt, Andrew, Abramson, Vandana, Dean, Emma, Haddad, Tufia C., Wesolowski, Robert, Ferrer-Playan, Jordi, Goddemeier, Thomas, Grombacher, Thomas, Dong, Jennifer, Fleuranceau-Morel, Patricia, Diaz-Padilla, Ivan, Plummer, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991212/ https://www.ncbi.nlm.nih.gov/pubmed/35393425 http://dx.doi.org/10.1038/s41523-022-00406-0

Ejemplares similares

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
por: Shapiro, Geoffrey I., et al.
Publicado: (2021)

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
por: Middleton, Mark R., et al.
Publicado: (2021)

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
por: Terranova, Nadia, et al.
Publicado: (2020)

Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system
por: Ni, Fubiao, et al.
Publicado: (2019)

The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
por: Schnoell, Julia, et al.
Publicado: (2023)

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer
por: Liu, Chaofan, et al.
Publicado: (2023)

Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
por: Gordon, Caroline, et al.
Publicado: (2019)

System for the high-level mission control of robotic tasks
por: Playan Garai, Jorge
Publicado: (2021)

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial
por: Mozgunov, Pavel, et al.
Publicado: (2022)

Avoiding the “Faux Equalizer”
por: Pritchett, Joshua C., et al.
Publicado: (2021)

Where are the boundaries? Automated pocket detection for druggability studies
por: Volkamer, Andrea, et al.
Publicado: (2010)

Aurora-A Kinase as a Promising Therapeutic Target in Cancer
por: D’Assoro, Antonino B., et al.
Publicado: (2016)

Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2016)

An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer
por: Vijayakumar, Jayanthi, et al.
Publicado: (2022)

Induced Pluripotent Stem Cell-Based Cancer Vaccines
por: Ouyang, Xiaoming, et al.
Publicado: (2019)

Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer
por: Scanlon, Maura, et al.
Publicado: (2012)

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
por: Kojima, Takashi, et al.
Publicado: (2018)

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
por: Zimmermann, Astrid, et al.
Publicado: (2022)

Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor–Induced Hyperglycemia: A Case Report
por: Bowman, Christopher, et al.
Publicado: (2017)

Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval
por: McRoy, Susan, et al.
Publicado: (2018)

RosettaSX: Reliable gene expression signature scoring of cancer models and patients
por: Kreis, Julian, et al.
Publicado: (2021)

An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results
por: Li, Xia, et al.
Publicado: (2012)

Ataxia and focal dystonia in Kallmann syndrome
por: Hernando‐Quintana, Natalia, et al.
Publicado: (2015)

Opinion: PARP inhibitors in cancer—what do we still need to know?
por: Wicks, Andrew J., et al.
Publicado: (2022)

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

Qualitative and Quantitative Image-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer
por: Golden, Daniel I., et al.
Publicado: (2018)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
por: Schlotman, Alyssa, et al.
Publicado: (2020)

Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment
por: Blaes, Anne, et al.
Publicado: (2015)

Cardiovascular comorbidity and death from COVID-19: Prevalence and differential characteristics
por: Playán-Escribano, Julia, et al.
Publicado: (2021)

Primeros ejercicios musicales
por: Tutt, David
Publicado: (2001)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

Closing the Knowledge Gap in the Long-Term Health Effects of Natural Disasters: A Research Agenda for Improving Environmental Justice in the Age of Climate Change
por: Ghosh, Arnab K., et al.
Publicado: (2022)

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
por: Lemech, Charlotte, et al.
Publicado: (2012)

Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence
por: Voskoboynik, Mark, et al.
Publicado: (2014)

Biomarkers in Advanced Colorectal Cancer: Challenges in Translating Clinical Research into Practice
por: Lemech, Charlotte, et al.
Publicado: (2011)

Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities
por: Fontana, Elisa, et al.
Publicado: (2020)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
por: Pernas, Sonia, et al.
Publicado: (2019)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_afgkdgl0j730gq6krs36nituja